Acknowledgements

This research was funded by Alcon Research, Ltd.

References

1. Schein OD, Tirlsch JM, Munoz B, Bandeen K, West S. Relation between signs and symptoms of dry eye in the elderly – A population based perspective. *Ophthalmology*. 1997;104(9):1395–1401.
2. Holly FJ, Lemp MA. Tear physiology and dry eyes. *Survey of Ophthalmology*. 1977;22(2):69–87.
3. Begley CG, Caffery B, Chalmers RL, Mitchell GL. Use of dry eye questionnaire to measure symptoms of ocular irritation in subjects with aqueous tear deficient dry eye. *Cornea*. 2002;21(7):664–670.
4. Doughty MJ, Fonn D, Richter D, Simpson T, Caffery B, Gordon K. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in subjects presenting to optometric practices across Canada. *Optom Vis Sci*. 1997;74(8):624–631.
5. Ousler GW, Emory TB, Welch D, Abelson MB. Factors that Influence the Inter-Blink Interval (IBI) as Measured by the Ocular Protection Index (OPI), (Poster Presentation) The Association of Research in Vision and Ophthalmology 2002.
6. Foulks GN. Challenges and pitfalls in clinical trials of treatments of dry eye. *The Ocular Surface*. 2003;1(1):20–30.
7. Cheng Y, Brown KM, Prud'homme RK. Characterization and intermolecular interactions of hydroxypropyl guar solutions. *Biomacromolecules*. 2002;3:456–461.
8. Yamada M, Mochizuki H, Kawai M, Yoshino M, Mashima Y. Fluorophotometric measurement of pH of human tear *in-vivo*. *Current Eye Research*. 1997;16(5):482–486.
9. Khurana AK, Chaaudhary R, Ahluwalia BK, Gupta S. Tear film profile in dry eye. *Acta Ophthalmologica*. 1991;9(1): 79–86.
10. Lemp, M.E. Report of the National Eye Institute workshop on clinical trials on dry eye. *CLAO Journal*. 1995;21:221–232.
11. Asgharian B, Nolen L, Meadows D, Stone R. Novel gel-forming ophthalmic polymer system for artificial tear solution. Abstract #2472 ARVO Meeting, May 2003.
12. Cohdosh J, Dix R, Howell R, Stroop W, Tseng S. Staining characteristics and antiviral activity of sulforhodamine B and lissamine green B. *Invest Ophthalmol Vis Sci*. 1994; 35(3):1046–1058.
13. Fujihara T, Murakami T, Nagano T, Nakamura M, Nakata K. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. Journal of Ocular Pharmacology and Therapeutics. 2002;18(4):363–370.
14. Agrueso P, Gipson IK. Epithelial mucins of the ocular surface: Structure, biosynthesis and function. *Experimental Eye Research*. 2001;73:281–289.
15. Gamache DA, Wei ZY, Weimer LK, Spellman JM, Yanni JM. Preservation of corneal ipntegrity by the mucin secretagogue 15(S)-HETE in a rabbit model of desiccation-induced dry eye. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3. David A. Sullivan *et al*. Kluwer Academic/Plenum Publishers, 2002.
16. Christensen M, Stein J, Stone R, Meadows D. Effect of Tear Film Break-up Time Extension by Artificial Tears in Dry Eye Patients. Abstract Submitted American Academy Optometry Meeting, Dec 2003.
17. Pollard S, Stone RP, Christensen MT, Ousler GW, Abelson MB. Extension in tear break-up time after instillation of HP-gar artificial tears substitute. *Invest Ophthalmol Vis Sci*. 2003;43:2489.
18. Christensen M, Stein JM, Stone R, Meadows D. Evaluation of the Effect on the Tear Film Break-up Time Extension by Artificial Tears in Dry Eye Patients. Schepens Eye Institute – Corneal Research Conference – Boston, MA; October 3–4 2003.